(Maria Elena Bottazzi)Jan 19, 2024 - Oct 31, 2024 Kingdom of Saudi Saudi Arabia
Academic Collaboration Agreement – Vaccine company for research, development and innovation (KSA)
Role Description: At the conclusion of the Training Program, fellows are expected to have attained the ability to plan, execute, and manage the core aspects of vaccine product development. The experience and knowledge acquired while working at TCCVD should enable participants to serve as leaders in establishing a Vaccine Development Center in the KSA.
Role: PI |
|
(Maria Elena Bottazzi)Jan 19, 2024 - Oct 31, 2024 PATH
PATH Mouse IPV
Role Description: Assess immune response to polio and rotavirus vaccines adjuvanted with CpG55.2 in a mouse model
Role: PI |
|
(Peter Hotez)Jun 1, 2023 - May 31, 2025 University of Malaya
CONSULTANCY SERVICE AGREEMENT - UNIVERSITI MALAYA
Role Description: This project is aimed at supporting the development of a hookworm mRNA vaccine program at TIDREC/UM.
Role: Co-investigator |
|
(Eric Dumonteil)Feb 16, 2023 - Jan 31, 2028 NIH via sub from Tulane University
Non-inferiority trial of a therapeutic vaccine against Chagas disease in naturally-infected rhesus macaques.
Role Description: Testing of the Tc24-C4 vaccine in NHPs
Role: Co-Investigator |
|
(Maria Elena Bottazzi)Apr 5, 2022 - Jun 30, 2022 The Bill and Melinda Gates Foundation via subaward from PATH, Inc
Mouse immunogenicity study of SARS-CoV-2 RBD 203-N1 formulated with Advax/CpG55.2. Main Goal: To compare the immune response elicited in mice vaccinated with SARS CoV-2
Role Description: To compare the immune response elicited in mice vaccinated with SARS CoV-2
RBD203-N1 + Advax/CpG55-2 vs. the response to SARS CoV-2 RBD203-N1 + Alum/CpG55-2.
Role: PI |
|
(Maria Elena Bottazzi)Apr 1, 2022 - Sep 30, 2022 MigVax SA
Understanding Cardiovascular Consequences of Thrombocyte in the SARS-CoV-2 Infection Process
Role Description: To produce multivariant SARS-CoV-2 RBD Proteins and two provide three RBD
variants
Role: PI |
|
(Maria Elena Bottazzi)Jan 1, 2022 - Jun 30, 2022 The Bill and Melinda Gates Foundation via subaward from PATH, Inc
Production and Characterization of murine mAbs against SARS and SARS-CoV2 variants
Role Description: Generate murine mAb that can differentiate SARS RBD between variants |
|
(Maria Elena Bottazzi)Aug 5, 2021 - Dec 31, 2022 Biological E Limited
Biological E Limited, Laboratory Services Agreement
Role Description: Company will provide (i) samples of sera collected from mice/rats/rabbits from
vaccine immunogenicity studies as well as (ii) pooled sera samples from multiple subjects that
have participated in company clinical trials. |
|
(Peter Hotez)Jul 30, 2021 - Jan 31, 2023 Fifth Generation, Inc
The next coronavirus vaccines: addressing variants-of-concern and emerging new coronaviruses
Role Description: Develop and produce broadly effective new vaccines that target the current VoCs for
SARS-CoV-2 but also additional, SARS-related coronaviruses.
Role: Project Leader |
|
(Maria Elena Bottazzi)Apr 15, 2021 - Apr 14, 2024 DARPA via Charles River Analytics
Personalized Protective Biosystem (Membranes and Comensal Helminths)
Role Description: The goal of the PPB program is to develop an integrated ensemble that
simultaneously eliminates protective equipment needs while increasing protection for the
individual against all CB threats.
Role: PI |
|
(Maria Elena Bottazzi)Sep 30, 2020 - Sep 29, 2024 DOD CDMRP
Development of a recombinant CspZ vacine against Lyme disease infection
Role Description: The overall goal of this collaboration is to define the protective mechanisms of the
CspZ-YA vaccine by evaluating the role of the antibodies induced by CspZ-YA vaccination and
understanding the mechanisms of the CspZ-YA-induced antibodies leading to bacterial
clearance.
Role: Sub-PI |
|
(Peter Hotez)Sep 1, 2020 - Sep 30, 2022 JPB Foundation
Coronavirus vaccine research
Role: Co-Investigator |
|
Apr 14, 2020 - Dec 31, 2022 Fifth Generation, Inc
SARS-CoV Vaccine Development
Role Description: To support development of a SARS-CoV vaccine from vialing through toxicology
testing.
Role: Project Leader |
|
(Maria Elena Bottazzi)Feb 1, 2020 - Jan 31, 2025 Wellcome Trust
Controlled Infection for Testing Efficacy of Hookworm Vaccines in Brazil
Role Description: Test new hookworm vaccine on human volunteers using qPCR.
Role: PI |
|
(Yi-Pin Lin)Feb 1, 2020 - Jan 31, 2024 NIH via NY State Dept of Health-Health Research Inc
Identification of the mechanism of protecting against a B. burgdorferi CspZ for the prevention of Lyme disease
Role Description: The overall goal of this collaboration is to define the protective mechanisms of the
CspZ-YA vaccine by evaluating the role of the antibodies induced by CspZ-YA vaccination and
understanding the mechanisms of the CspZ-YA-induced antibodies leading to bacterial
clearance.
Role: Sub-PI |
|
(Peter Hotez)Apr 1, 2019 - Mar 31, 2021 NIH
A novel mucosal trichuriasis vaccine for TH2 immune protection
Role: Co-Investigator |
|
R13AI142711 (BOTTAZZI, MARIA ELENA)Feb 6, 2019 - Apr 30, 2019 NIH
2019 Tropical Infectious Diseases
Role: Principal Investigator |
|
(Maria Elena Bottazzi)Jan 1, 2019 - Dec 31, 2025 Instituto Carlos Slim de la Salud
Chagas Vaccine Initiative
Role Description: The overall goal of the project is to advance the first therapeutic Chagas disease
vaccine prototype through a First-in-Human Phase 1 clinical trial.
Role: PI |
|
(Peter Hotez)Sep 30, 2018 - Sep 9, 2024 CDMRP sub through GWU
Phase I/IIb Testing of the Sm-TSP-2 Schistosomiasis Vaccine in Uganda
Role Description: The overall goal of this proposal is to perform a Phase I/IIb clinical trial to evaluate the safety
and immunogenicity of the Sm-TSP-2/Alhydrogel schistosomiasis vaccine in African adults.
Role: Project Leader |
|
W81XWH-17-2-0050 (Peter Hotez)Sep 15, 2017 - Sep 14, 2020 CDMRP
A vaccine to prevent leishmaniasis
Role: Co-Investigator |
|
2RO1AI078314-06A1 (Sara Lustigman)Apr 11, 2017 - Feb 28, 2022 New York Blood Center
TEh Development of a recombinant vaccine against onchocerciasis
Role: BCM Principal Invvestigator |